Myocardial perfusion imaging laboratory efficiency with the use of regadenoson compared to adenosine and dipyridamole

References

• Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2010;122:2748-64
   PubMed Web of Science ®Google Scholar
• Mosca L, Benjamin EJ, Berra K, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women–2011 update: a guideline from the american heart association. Circulation 2011;123:1243-62
   PubMed Web of Science ®Google Scholar
• Kung HC, Hoyert DL, Xu J, et al. Deaths: final data for 2005. Natl Vital Stat Rep 2008;56:1-120
   PubMedGoogle Scholar
• Roger VL, Go AS, Lloyd-Jones DM, et al. Executive summary: heart disease and stroke statistics–2012 update: a report from the American Heart Association. Circulation 2012;125:188-97
   PubMed Web of Science ®Google Scholar
• Lloyd-Jones DM, Larson MG, Beiser A, et al. Lifetime risk of developing coronary heart disease. Lancet 1999;353:89-92
   PubMed Web of Science ®Google Scholar
• Heidenreich PA, Trogdon JG, Khavjou OA, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation 2011;123:933-44
   PubMed Web of Science ®Google Scholar
• Russell MW, Huse DM, Drowns S, et al. Direct medical costs of coronary artery disease in the United States. Am J Cardiol 1998;81:1110-5
   PubMed Web of Science ®Google Scholar
• Vesely MR, Dilsizian V. Nuclear cardiac stress testing in the era of molecular medicine. J Nucl Med 2008;49:399-413
   Google Scholar
• Botvinick EH. Current methods of pharmacologic stress testing and the potential advantages of new agents. J Nucl Med Technol 2009;37:14-25
   PubMedGoogle Scholar
• Adenosine (adenosine) injection (Drug Label) Manufactured by Gland Pharma, Hyderabad, India. Revised 06/2007. DailyMed, U.S. National Library of Medicine, 2007. http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ab2edabd-e57d-4754-9822-93bd17af9e88. Accessed 2012
   Google Scholar
• Dipyridamole (dipridamole) solution. (Drug Label) Manufactured by Anazeo Health Corporation, Tampa, FL. Revised 05/2012. DailyMed, U.S. National Library of Medicine, 2012. http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c76c3c6f-c3e0-4e35-ab01-5468585e0d9d. Accessed 2012
   Google Scholar
• Henzlova M, Cerqueira M, Taillefer R, et al. ASNC Imaging Guidelines For Nuclear Cardiology Procedures. J Nucl Cardiol 2009;16:331
   Google Scholar
• Cerqueira MD, Verani MS, Schwaiger M, et al. Safety profile of adenosine stress perfusion imaging: results from the Adenoscan Multicenter Trial Registry. J Am Coll Cardiol 1994;23:384-9
   PubMed Web of Science ®Google Scholar
• Ranhosky A, Kempthorne-Rawson J. The safety of intravenous dipyridamole thallium myocardial perfusion imaging. Intravenous Dipyridamole Thallium Imaging Study Group. Circulation 1990;81:1205-9
   PubMed Web of Science ®Google Scholar
• Lexiscan (regadenoson) injection (Drug Label). Manufactured by Astellas Pharma US, Inc. Revised 07/2012. DailyMed, U.S. National Library of Medicine, 2012. http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=75982. Accessed 2012
   Google Scholar
• Henzlova MJ, Cerqueira MD, Mahmarian JJ, et al; Quality Assurance Committee of the American Society of Nuclear C. Stress protocols and tracers. J Nucl Cardiol 2006;13:e80-90
   Google Scholar
• Lapeyre AC 3rd, Goraya TY, Johnston DL, et al. The impact of caffeine on vasodilator stress perfusion studies. J Nucl Cardiol 2004;11:506-11
   Google Scholar
• Verani MS. Adenosine thallium 201 myocardial perfusion scintigraphy. Am Heart J 1991;122:269-78; discussion 302–6
   Google Scholar
• Bengalorkar GM, Bhuvana K, Sarala N, et al. Regadenoson. J Postgrad Med 2012;58:140-6
   Google Scholar
• Cerqueira MD, Nguyen P, Staehr P, et al; Investigators A-MT. Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging integrated ADVANCE-MPI trial results. JACC Cardiovasc Imag 2008;1:307-16
   PubMed Web of Science ®Google Scholar
• Iskandrian AE, Bateman TM, Belardinelli L, et al. Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: results of the ADVANCE phase 3 multicenter international trial. J Nucl Cardiol 2007;14:645-58
   PubMed Web of Science ®Google Scholar
• Buhr C, Gossl M, Erbel R, et al. Regadenoson in the detection of coronary artery disease. Vasc Health Risk Manag 2008;4:337-40
   PubMedGoogle Scholar
• Leaker BR, O'Connor B, Hansel TT, et al. Safety of regadenoson, an adenosine A2A receptor agonist for myocardial perfusion imaging, in mild asthma and moderate asthma patients: a randomized, double-blind, placebo-controlled trial. J Nucl Cardiol 2008;15:329-36
   PubMed Web of Science ®Google Scholar
• Thomas GS, Tammelin BR, Schiffman GL, et al. Safety of regadenoson, a selective adenosine A2A agonist, in patients with chronic obstructive pulmonary disease: a randomized, double-blind, placebo-controlled trial (RegCOPD trial). J Nucl Cardiol 2008;15:319-28
   PubMed Web of Science ®Google Scholar
• Gordi T, Blackburn B, Lieu H. Regadenoson pharmacokinetics and tolerability in subjects with impaired renal function. J Clin Pharmacol 2007;47:825-33
   PubMed Web of Science ®Google Scholar
• Hendel RC, Bateman TM, Cerqueira MD, et al. Initial clinical experience with regadenoson, a novel selective A2A agonist for pharmacologic stress single-photon emission computed tomography myocardial perfusion imaging. J Am Coll Cardiol 2005;46:2069-75
   PubMed Web of Science ®Google Scholar
• Lexiscan Product Monograph. In. Deerfield, IL: Astellas Pharma US Inc,
   Google Scholar
• Johnson SG, Peters S. Advances in pharmacologic stress agents: focus on regadenoson. J Nucl Med Technol 2010;38:163-71
   Google Scholar
• Trotter MJ, Larsen ET, Tait N, et al. Time study of clinical and nonclinical workload in pathology and laboratory medicine. Am J Clin Pathol 2009;131:759-67
   Google Scholar
• Weigl M, Muller A, Zupanc A, et al. Participant observation of time allocation, direct patient contact and simultaneous activities in hospital physicians. BMC Health Serv Res 2009;9:110
   PubMedGoogle Scholar
• Banner L, Olney CM. Automated clinical documentation: does it allow nurses more time for patient care? Comput Inform Nurs 2009;27:75-81
   Google Scholar
• Prenner BM, Bukofzer S, Behm S, et al. A randomized, double-blind, placebo-controlled study assessing the safety and tolerability of regadenoson in subjects with asthma or chronic obstructive pulmonary disease. J Nucl Cardiol 2012;19:681-92
   PubMed Web of Science ®Google Scholar